ROLE OF MgSO4 IN NEURO PROTECTION IN PATIENTS PRESENTING WITH PRETERM LABOUR BETWEEN 28 TO 32 WEEKS

A IFTIKHAR; R SADAF

doi:10.54112/bcsrj.v2024i1.1492

Authors

A IFTIKHAR Department of Gynae, B Ward MTI HMC Peshawar, Pakistan
R SADAF Department of Gynae, B Ward MTI HMC Peshawar, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1492

Keywords:

MgSO4; Neuroprotection; Preterm Labour

Abstract

Preterm birth (PTB) is a major contributor to neonatal morbidity and mortality, with significant neurological complications, including cerebral palsy and developmental delays. Magnesium sulfate (MgSO₄) has been proposed as a neuroprotective agent for preterm neonates, but its efficacy requires further evaluation in clinical settings. Objectives: To determine the role of MgSO4 in neuroprotection in patients presenting with preterm labor between 28 to 32 weeks of gestation. Methods: This study commenced after obtaining approval from the hospital's ethical board and research committee. Eligible patients who provided written informed consent were recruited from inpatient and outpatient departments. The study's purpose and benefits were explained to participants, ensuring confidentiality and clarifying that participation would not affect future medical care. Demographic and baseline data were documented, including age, gestational age, parity, BMI, residence, and comorbidities. Blocked randomization was used to allocate patients equally to Group A or Group B. Group A received MgSO₄ starting with a 4 g intravenous infusion over 20 minutes, followed by a maintenance dose of 1 g per hour via infusion pump until delivery. Group B received a placebo. Deliveries were conducted in the labor unit following hospital protocols for high-risk pregnancies, with instrumental assistance or cesarean sections performed as needed under the guidance of a consultant gynecologist. Newborns were transferred to the neonatal intensive care unit and observed for 48 hours for seizures, based on operational definitions. Data were collected by the researcher using a structured proforma. Data was analyzed using SPSS version 25. Results: The study involved 154 participants with a mean age of 32.62. Group A showed significantly higher neuroprotection (94.8%) than Group B (79.2%), with a p-value of 0.004. Factors like age, gestation, parity, and comorbidities had no significant impact on outcomes in either group. Conclusion: MgSO4 effectively reduces neurological risks in preterm neonates, emphasizing timely use, safety, and feasibility in standard care, with further research needed for validation.

Downloads

Download data is not yet available.

References

Onishi J. Epidemiology and Incidence of Preterm Delivery. Preterm Labor and Delivery. 2020:17-25.

Hirides P, Hirides S, Hirides C. Cerebral Palsy and Difficult Birth. A Scoping Review. Journal of Neonatal-Perinatal Medicine. 2023;16(2):209-19.

da Rocha RSBA. hypoxia-ischemia in neonatal brain: a translational approach to its consequences. 2023.

Dadashaliha M, Hoorshad S, Fallah S. Comparison of the effect of simultaneous administration of magnesium sulfate and indomethacin with the administration of magnesium sulfate alone in inhibiting premature birth. 2024.

Dickerson AG, Joseph CA, Kashfi K. Advances in Preeclampsia Management: Addressing Racial Disparities and Improving Outcomes. 2024.

Mathew AA, Panonnummal R. A mini review on the various facets effecting brain delivery of magnesium and its role in neurological disorders. Biological Trace Element Research. 2023;201(9):4238-53.

Jafar U, Nawaz A, Zahid MZA, Saddiqah S, Zainab F, Naeem S, et al. Magnesium sulfate for fetal neuroprotection in preterm labor: an updated systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics. 2024:1-12.

Goojha C. Can magnesium sulphate provide neuroprotection in preterm infants? A literature review. 2023.

Bachnas MA, Akbar MIA, Dachlan EG, Dekker G. The role of magnesium sulfate (MgSO4) in fetal neuroprotection. The Journal of Maternal-Fetal & Neonatal Medicine. 2021;34(6):966-78.

Crowther CA, Middleton PF, Wilkinson D, Ashwood P, Haslam R, Group MS. Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA)-study protocol. BMC pregnancy and childbirth. 2013;13:1-9.

Le Dieu-Lugon B, Dupré N, Derambure C, Janin F, Gonzalez BJ, Marret S, et al. Effect of neuroprotective magnesium sulfate treatment on brain transcription response to hypoxia ischemia in neonate mice. International Journal of Molecular Sciences. 2021;22(8):4253.

Hauth J, Goldenberg R, Nelson K, DuBard M, Peralta M, Gaudier F. Reduction of cerebral palsy with maternal MgSO4 treatment in newborns weighing 500-1000 g. Am J Obstet Gynecol. 1995;172(1 Pt 2):419.

Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. Jama. 1996;276(22):1805-10.

Wiswell T, Graziani L, Caddell J, Vecchione N, Stanley C, Spitzer A. Maternally-administered Magnesium Sulfate (MgSO4) protects against early brain injury and long-term adverse neurodevelopmental outcomes in preterm infants: a Prospective Study. 1502. Pediatric Research. 1996;39(4):253-.

FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. American journal of perinatology. 1997;14(05):303-7.

Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and risk of neonatal death. American journal of obstetrics and gynecology. 1998;178(1):1-6.

Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, et al. The effect of maternal magnesium sulfate treatment on neonatal morbidity in≤ 1000-gram infants. American journal of perinatology. 1998;15(11):635-41.

Paneth N, Jetton J, Pinto-Martin J, Susser M, Group NBHSA. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. Pediatrics. 1997;99(5):e1-e.

Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, et al. Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2001;85(1):F13-F7.

Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M. Protective effect of MgSO4 infusion on NMDA receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain research. 1994;644(1):144-9.

Shogi T, Miyamoto A, Ishiguro S, Nishio A. Enhanced release of IL‐1β and TNF‐α following endotoxin challenge from rat alveolar macrophages cultured in low‐Mg 2+ medium. Magnesium research. 2003;16(2):111-9.

Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Current treatment options in cardiovascular medicine. 2003;5(6):441-9.

Rantonen T, Grönlund J, Jalonen J, Ekblad U, Kääpä P, Kero P, et al. Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clinical physiology and functional imaging. 2002;22(1):13-7.

Macdonald RL, Curry DJ, Aihara Y, Zhang Z-D, Jahromi BS, Yassari R. Magnesium and experimental vasospasm. Journal of neurosurgery. 2004;100(1):106-10.

Hallak M, Cotton DB. Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: assessment of amniotic fluid, blood, and brain concentrations. American journal of obstetrics and gynecology. 1993;169(2):427-31.